Michael Perry S.'s Insider Trades & SAST Disclosures
Michael Perry S.'s most recent trade in Arrowhead Pharmaceuticals Inc. was a trade of 16,733 Common Stock done at an average price of $23.0 . Disclosure was reported to the exchange on Dec. 18, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Michael Perry S..To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals ... | Michael S. Perry | Director | Grant, award, or other acquisition of securities at price $ 22.99 per share. | 18 Dec 2024 | 16,733 | 131,490 (0%) | 0% | 23.0 | 384,692 | Common Stock |
| Arrowhead Pharmaceuticals ... | Michael Perry S. | Director | Grant, award, or other acquisition of securities at price $ 25.41 per share. | 15 Dec 2023 | 14,987 | 114,754 (0%) | 0% | 25.4 | 380,820 | Common Stock |
| Arrowhead Pharmaceuticals ... | Michael S. Perry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2023 | 7,867 | 99,767 (0%) | 0% | 0 | Common Stock | |
| Arrowhead Pharmaceuticals ... | Michael S. Perry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2023 | 4,593 | 4,593 | - | - | Common Stock | |
| AVITA Medical Inc | Michael S. Perry | Director | Sale of securities on an exchange or to another person at price $ 7.18 per share. | 21 Nov 2022 | 150,000 | 229,543 | - | 7.2 | 1,077,000 | Common Stock |
| AVITA Medical Inc | Michael S. Perry | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Nov 2022 | 150,000 | 0 | - | - | Stock Options (Right to Buy) | |
| AVITA Medical Inc | Michael S. Perry | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.99 per share. | 21 Nov 2022 | 150,000 | 379,543 | - | 6.0 | 898,500 | Common Stock |
| AVITA Medical Inc | Michael S. Perry | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 3,450 | 6,900 | - | - | Stock Options (Right to Buy) | |
| AVITA Medical Inc | Michael S. Perry | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 2,980 | 300,983 | - | 0 | Common Stock | |
| AVITA Medical Inc | Michael S. Perry | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 01 Jun 2022 | 23,754 | 297,958 | - | 0 | Common Stock | |
| AVITA Medical Inc | Michael S. Perry | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2022 | 23,753 | 326,564 | - | 0 | Common Stock | |
| AVITA Medical Inc | Michael S. Perry | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 8.74 per share. | 23 Feb 2022 | 10,812 | 321,712 | - | 8.7 | 94,497 | Common Stock |
| AVITA Medical Inc | Michael S. Perry | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2022 | 5,960 | 332,524 | - | 0 | Common Stock | |
| AVITA Medical Inc | Michael S. Perry | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2022 | 3,450 | 3,450 | - | - | Stock Options (Right to Buy) | |
| Arrowhead Pharmaceuticals ... | Michael S. Perry | Director | Sale of securities on an exchange or to another person at price $ 64.30 per share. | 03 Jan 2022 | 2,628 | 87,372 (0%) | 0% | 64.3 | 168,980 | Common Stock |
| Arrowhead Pharmaceuticals ... | Michael S. Perry | Director | Sale of securities on an exchange or to another person at price $ 65.12 per share. | 03 Jan 2022 | 1,600 | 85,772 (0%) | 0% | 65.1 | 104,192 | Common Stock |
| Arrowhead Pharmaceuticals ... | Michael S. Perry | Director | Sale of securities on an exchange or to another person at price $ 66.25 per share. | 03 Jan 2022 | 272 | 85,500 (0%) | 0% | 66.3 | 18,020 | Common Stock |
| AVITA Medical Inc | Michael S. Perry | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2021 | 23,820 | 302,811 | - | - | Common Stock | |
| AVITA Medical Inc | Michael S. Perry | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2021 | 23,820 | 278,991 | - | - | Common Stock | |
| AVITA Medical Inc | Michael S. Perry | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2021 | 23,800 | 255,171 | - | - | Common Stock | |
| AVITA Medical Inc | Michael S. Perry | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2021 | 13,800 | 13,800 | - | - | Stock Options (Right to Buy) | |
| AVITA Medical Inc | Michael S. Perry | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2021 | 13,800 | 13,800 | - | - | Stock Options (Right to Buy) | |
| AVITA Medical Inc | Michael S. Perry | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2021 | 13,800 | 13,800 | - | - | Stock Options (Right to Buy) | |
| AVITA Medical Inc | Michael S. Perry | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2021 | 23,754 | 248,858 | - | 0 | Common Stock | |
| AVITA Medical Inc | Michael S. Perry | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 20.68 per share. | 01 Sep 2021 | 11,220 | 237,638 | - | 20.7 | 232,030 | Common Stock |
| AVITA Medical Inc | Michael S. Perry | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 17.33 per share. | 02 Jun 2021 | 23,000 | 225,104 | - | 17.3 | 398,590 | Common Stock |
| Arrowhead Pharmaceuticals ... | Michael S. Perry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2021 | 9,000 | 94,000 (0%) | 0% | 0 | Common Stock | |
| Arrowhead Pharmaceuticals ... | Michael S. Perry | Director | Sale of securities on an exchange or to another person at price $ 76.09 per share. | 01 Jan 2021 | 4,000 | 90,000 (0%) | 0% | 76.1 | 304,360 | Common Stock Sold |
| AVITA Medical Inc | Michael S. Perry | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2020 | 83,333 | 431,572 | - | 0 | Common Stock | |
| AVITA Medical Inc | Michael S. Perry | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2020 | 25,000 | 150,000 | - | - | Stock Options (Right to Buy) | |
| AVITA Medical Inc | Michael S. Perry | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 26.02 per share. | 09 Sep 2020 | 20,000 | 404,444 | - | 26.0 | 520,400 | Common Stock |
| AVITA Medical Inc | Michael S. Perry | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 26.26 per share. | 09 Sep 2020 | 7,128 | 424,444 | - | 26.3 | 187,181 | Common Stock |
| Arrowhead Pharmaceuticals ... | Michael S. Perry | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2020 | 25,000 | 0 | - | - | Common Stock (right to buy) | |
| Arrowhead Pharmaceuticals ... | Michael S. Perry | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.20 per share. | 14 May 2020 | 25,000 | 85,000 (0%) | 0% | 4.2 | 105,000 | Common Stock |
| Arrowhead Pharmaceuticals ... | Michael S. Perry | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.19 per share. | 14 May 2020 | 15,000 | 60,000 (0%) | 0% | 5.2 | 77,850 | Common Stock |
| Arrowhead Pharmaceuticals ... | Michael S. Perry | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2020 | 15,000 | 25,000 | - | - | Common Stock (right to buy) | |
| Arrowhead Pharmaceuticals ... | Michael S. Perry | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 14 May 2020 | 15,000 | 35,000 (0%) | 0% | 2.2 | 32,850 | Common Stock |
| Arrowhead Pharmaceuticals ... | Michael S. Perry | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2020 | 15,000 | 50,000 | - | - | Common Stock (right to buy) | |
| Arrowhead Pharmaceuticals ... | Michael S. Perry | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2020 | 10,000 | 40,000 | - | - | Common Stock (right to buy) | |
| Arrowhead Pharmaceuticals ... | Michael S. Perry | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.62 per share. | 14 May 2020 | 10,000 | 45,000 (0%) | 0% | 2.6 | 26,200 | Common Stock |
| Arrowhead Pharmaceuticals ... | Michael S. Perry | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.75 per share. | 14 May 2020 | 7,000 | 15,000 (0%) | 0% | 4.8 | 33,250 | Common Stock |
| Arrowhead Pharmaceuticals ... | Michael S. Perry | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2020 | 7,000 | 70,000 | - | - | Common Stock (right to buy) | |
| Arrowhead Pharmaceuticals ... | Michael S. Perry | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.01 per share. | 14 May 2020 | 5,000 | 20,000 (0%) | 0% | 2.0 | 10,050 | Common Stock |
| Arrowhead Pharmaceuticals ... | Michael S. Perry | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2020 | 5,000 | 65,000 | - | - | Common Stock (right to buy) | |
| Arrowhead Pharmaceuticals ... | Michael S. Perry | Director | Sale of securities on an exchange or to another person at price $ 35.71 per share. | 12 May 2020 | 29,900 | 14,100 (0%) | 0% | 35.7 | 1,067,729 | Common Stock |
| Arrowhead Pharmaceuticals ... | Michael S. Perry | Director | Sale of securities on an exchange or to another person at price $ 36.42 per share. | 12 May 2020 | 6,100 | 8,000 (0%) | 0% | 36.4 | 222,162 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges